Rare disease biotech Electra picks commercially-minded Kathy Dong as next CEO
![](https://electra-therapeutics.com/wp-content/uploads/2022/01/Group-6161@2x.png)
Electra Therapeutics is several years away from having a commercial product. And yet, the biotech’s new CEO Kathy Dong’s resume is stacked with experience on marketing and launching drugs—most notably, Gilead’s Sovaldi and Harvoni.